WHO mass-testing three potential Covid-19 drugs

Published August 12, 2021
The drugs were chosen by an independent expert panel for their potential in reducing the risk of death in hospitalised Covid-19 patients. — AFP/File
The drugs were chosen by an independent expert panel for their potential in reducing the risk of death in hospitalised Covid-19 patients. — AFP/File

GENEVA: The World Health Organisation on Wednesday announced major international trials of three drugs to find out whether they improve the condition of hospitalised Covid-19 patients.

Artesunate, imatinib and infliximab will be tested on thousands of volunteer patients in more than 600 hospitals in 52 countries.

“Finding more effective and accessible therapeutics for Covid-19 patients remains a critical need,” said WHO director general Tedros Adhanom Ghebreyesus.

Artesunate is a treatment for severe malaria; imatinib a drug used for certain cancers and infliximab a treatment for immune system disorders such as Crohn’s and rheumatoid arthritis.

The coordinated research across dozens of countries allows the trial to assess multiple treatments using a single protocol, thereby generating robust estimates on the effect a drug may have on mortality, including moderate effects, said the WHO.

The drugs were chosen by an independent expert panel for their potential in reducing the risk of death in hospitalised Covid-19 patients.

They were donated for the trial by their manufacturers and are already being shipped out to the hospitals involved.

The testing of artesunate, imatinib and infliximab on Covid-19 patients is the second stage of the WHO’s Solidarity hunt for effective treatments against the killer disease.

Previously, four drugs were evaluated by the Solidarity trial, involving almost 13,000 patients in 500 hospitals across 30 countries. The provisional results issued in October showed that remdesivir, hydroxychloroquine, lopinavir and interferon had little or no effect on hospitalised patients with Covid-19. The final results are due out next month.

“We already have many tools to prevent, test for and treat Covid-19, including oxygen, dexamethasone and IL-6 blockers. But we need more, for patients at all ends of the clinical spectrum, from mild to severe disease,” Tedros told a news conference.

The WHO Covid-19 Therapeutics Advisory Group recommended evaluating the anti-inflammatory properties of artesunate, which has been extensively used in the treatment of malaria and other parasitic diseases for more than 30 years, and is regarded as being very safe.

A randomised clinical trial in the Netherlands reported that imatinib, a small molecule tyrosine kinase inhibitor, might confer clinical benefit in hospitalised Covid-19 patients.

Meanwhile infliximab has shown favourable efficacy and safety in restricting broad spectrum inflammation,

including in the elderly populations who are the most clinically vulnerable to Covid-19.

Published in Dawn, August 12th, 2021

Opinion

Editorial

Disquiet on the western front
Updated 07 Dec, 2022

Disquiet on the western front

IT is very difficult for Pakistan to be delinked from Afghanistan, because of reasons of geography and history.
Fuel from Russia
07 Dec, 2022

Fuel from Russia

THE apparent headway made with Russia for the purchase of its crude oil, petrol and diesel at discounted prices is a...
More women SHOs
07 Dec, 2022

More women SHOs

IT is encouraging to see more employment avenues opening up for women in Pakistan, with an increasing number of...
Is there a plan?
Updated 06 Dec, 2022

Is there a plan?

The ball currently is in Imran's court, but it appears he is stumped as to what to do with it.
Riverfront concerns
06 Dec, 2022

Riverfront concerns

THE door-to-door drive being launched by a group of landowners to mobilise affected communities against what they...
Morality police out
06 Dec, 2022

Morality police out

FOR several months, Iran has been rocked by unprecedented protests, sparked by the death on Sept 16 of Mahsa Amini, ...